MFS
VRDN icon

Mirabella Financial Services’s Viridian Therapeutics VRDN Stock Holding History

Mirabella Financial Services’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,769
Closed -$753K – 606
2022
Q4 		$753K Buy
+25,769
New +$594K 0.07% 156

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Mirabella Financial Services's VRDN Position: Q1 2023 in Review

Mirabella Financial Services sold out of Viridian Therapeutics (VRDN) in Q1 2023, closing a stake of 25,769 shares — an estimated $753K sold.

Mirabella Financial Services first reported a position in VRDN in Q4 2022 and held it in 1 quarter. The position peaked at $753K in Q4 2022. 135 funds tracked by Wall St. Rank hold VRDN as of Q1 2023.

  • Mirabella Financial Services reported no remaining Viridian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mirabella Financial Services sold 25,769 Viridian Therapeutics shares in Q1 2023, an estimated $753K.
  • Mirabella Financial Services first reported a position in Viridian Therapeutics in Q4 2022 and held it in 1 quarter.
  • Mirabella Financial Services's Viridian Therapeutics position peaked at $753K in Q4 2022.
  • 135 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2023.

Based on Mirabella Financial Services's 13F filing for Q1 2023, filed 12 May 2023.